Gennova Bipharmaceuticals to create dedicated malaria vaccine unit

Mumbai June 17 (UNI) Gennova Biopharmaceuticals Ltd (GBL) is collaborating with the PATH Malaria Vaccine Initiative (MVI) to create a dedicated malaria vaccine manufacturing facility.

PATH MVI is a focused vaccine development program created through a grant from the Bill&Melinda Gates Foundation, a Gennova Biopharmaceuticals release here said .

Under the GBL-MVI agreement, MVI will provide partial financial support to GBL to establish a cGMP compliant manufacturing facility able to produce recombinant protein-based malaria vaccine candidates.

Dr. Sanjay Singh, CEO, Gennova Biopharmaceuticals said, "The funding was based on the scientific and business synergies that exist between the two organizations." MVI is providing financial support for the first time to equip a dedicated recombinant protein manufacturing facility to produce cGMP grade malaria vaccine candidates for use in Phase I and Phase II clinical trials.

GBL has created a consortium through which the US National Institutes of Health will conduct laboratory animal trials for testing the efficacy of the vaccine candidates produced at GBL. The National Institute of Malaria Research (NIMR), India will conduct epidemiological studies using human sera from malarial endemic regions in India. NIMR will also conduct Phase I and II human clinical trials for the selected vaccine candidates at its well-established clinical trial centres.

UNI VK OBB AG1730